NCT05221372Recruiting
ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors
Source: ClinicalTrials.gov · Last updated 18 Feb 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1300 (estimated)
- First submitted
- 10 Jan 2022
- Start date
- 2 Feb 2017
- Primary completion date
- 1 Jan 2031
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Lung cancer
- NCT number
- NCT05221372
What you commit to
- Study type: Observational
- Planned participants: 1300
- From 2 Feb 2017 to the primary completion date, 1 Jan 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable to draw blood for study purposes
Who the study is looking for
- Age ≥ 18 years
- Able to understand the written informed and able to give informed consent
- Locally advanced or metastatic NSCLC with oncogenic driver mutation
- Treatment with TKI according to standard of care
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.